Research and Markets: Pharma YouTube Channels: Content and Comment Brings Together the Thought Leadership of Five of the I

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4fc234/youtube_cha) has announced the addition of the "Pharma YouTube Channels: Content and Comment" report to their offering.

Popular video sharing site YouTube is the third busiest website in the world, visited by almost 109 million unique users each month. Nearly a day and a half's worth of content is uploaded by users on to its servers every minute, and channel managers from 15 pharmaceutical companies are included in their numbers.

Whilst YouTube offers the opportunity to reach a vast consumer audience at relatively low cost, the unfamiliar nature of the video sharing environment to the Pharma industry, with all the attendant issues that a heavily regulated industry faces when participating in a social web environment, has meant that Pharma presences upon the site have been slow to develop.

However, a number of companies have begun to forge effective presences around the channels they have created and the content that they are developing and sharing, each developing their own set of strategic and tactical best practices from the lessons they have learned from their activities.

Pharma YouTube Channels: Content and Comment brings together the thought leadership of five of the industry figures who speak with authority to the subject of Pharma's use of YouTube through their direct participation or oversight: Rob Halper (Johnson & Johnson), Andrew Widger (Pfizer), Gary Monk (Janssen), James Musick (Genentech) and John Pugh (Boehringer)

Containing a contextual introduction, statistics, definitions, charts and five exhaustive interviews presented in a round table question and answer format for ease of reading, the report is essential reading for those interested in the development of the industry's presence on the social web and the uses to which video sharing are being put.

The report includes:

  • Expert insights from the architects of and spokespersons for five of the leading Pharma industry YouTube presences
  • Comprehensive explanations of the thinking behind the strategic planning and tactical implementation of Pharma YouTube channels.

Key features

  • Contextual introduction providing the latest data regarding YouTube's reach and influence as a video-sharing channel
  • Stage-by-stage accounts of the development of Pharma YouTube channels
  • In-depth analysis of the types of content published, issues around the facilitation of user engagement, metrics used, and the measures of success utilised
  • Conclusion featuring suggestions as to best practice guidelines in the planning, implementation, and maintenance of a Pharma YouTube channel

Key Topics Covered:

  • Executive Summary
  • Methodology
  • Introduction
  • Participants
  • Strategy, Planning, and Production
  • Strategy
  • Planning
  • Production
  • Content
  • Types of Content
  • Local Content, Global Content
  • Content popularity
  • Playlist Considerations
  • Tactical Considerations
  • Tactics Search Engine Optimization
  • Tactics Video Length
  • Comments and Other Engagement
  • Metrics and Measurement
  • Defining Success on YouTube
  • Conclusion: Shared Learnings and Best Practices
  • Appendix
  • YouTube Channel Data

For more information visit http://www.researchandmarkets.com/research/4fc234/youtube_cha



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Technology  Internet  Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.